Trials / Completed
CompletedNCT00724971
Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab
A Phase 1 Study Of Cmc-544 Administered In Combination With Rituximab In Subjects With B-cell Non-hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To assess the tolerability and the initial safety profile of Inotuzumab Ozogamicin (CMC-544) in combination with Rituximab in patients with B-Cell Non-Hodgkin's lymphoma (NHL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inotuzumab Ozogamicin (CMC-544) | 1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs. |
| DRUG | Rituximab (Rituxan) | 375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs. |
Timeline
- Start date
- 2008-07-04
- Primary completion
- 2010-03-10
- Completion
- 2010-03-10
- First posted
- 2008-07-30
- Last updated
- 2019-03-15
- Results posted
- 2019-03-15
Locations
4 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00724971. Inclusion in this directory is not an endorsement.